Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 7/20 | 0.74 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.72 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.72 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.67 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.67 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.67 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.63 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.63 |
| ▸ | AHCY | P23526 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40635 | 0.87 | ADORA3 (0.72) | ADORA3ADORA1 | |
| SCHEMBL19843957 | 0.87 | ADORA3 (0.72) | ADORA3ADORA1DOT1LPRMT1ADORA2A | |
| SCHEMBL17234118 | 0.87 | ADORA3 (0.72) | ADORA3ADORA1 | |
| SCHEMBL3164693 | 0.87 | ADORA3 (0.72) | ADORA3ADORA1 | |
| SCHEMBL14929512 | 0.87 | ADORA3 (0.72) | ADORA3ADORA1 | |
| SCHEMBL23647923 | 0.87 | ADORA3 (0.72) | ADORA3ADORA1 | |
| SCHEMBL40634 | 0.87 | ADORA3 (0.72) | ADORA3ADORA1 | |
| SCHEMBL8425718 | 0.87 | ADORA3 (0.72) | ADORA3ADORA1 | |
| SCHEMBL20801120 | 0.87 | ADORA3 (0.72) | ADORA3ADORA1 | |
| SCHEMBL14946390 | 0.87 | ADORA3 (0.72) | ADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | UTI LIMITED PARTNERSHIP (CA) | 2018-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180037601-A1 | Nucleoside-Based Anti-Bacterial and Anti-Protozoan Drugs | PNP, NUDT1, SLC29A1 | ADORA3 78/4885PRMT5 2333/4885WDR77 1390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.